On Tuesday, Barclays (LON:BARC) reaffirmed its Overweight rating on ConvaTec Group Plc (LON:CTEC:LN) (OTC: CNVVY), with a price target of £3.20. The endorsement follows ConvaTec's latest trading update and a subsequent management presentation. Barclays drew attention to three main points from the discussion that underscored the company's potential through 2025.
Firstly, ConvaTec's management expressed confidence in achieving significant margin improvement in the second half of 2024, which is expected to carry over into 2025. This optimism is attributed to easing inflation pressures, increased productivity, and sustained top-line growth.
A key factor in margin expansion is the ongoing automation of ConvaTec's factories, with only one of its five larger factories fully automated to date. Inflation is also projected to stabilize within a 2% to 4% range.
Furthermore, the company anticipates double-digit growth in earnings per share (EPS) in 2025, regardless of the outcome of the LCD decision.
The second takeaway from the presentation focused on InnovaMatrix, ConvaTec's advanced wound care product. The company has not observed any adverse effects from the LCD in 2024, though the impact in 2025 remains uncertain.
Despite this, the business has seen approximately 40% growth year-to-date, with strong sales momentum outside of venous leg ulcers (VLU) and diabetic foot ulcers (DFU). This segment now accounts for about 25% of sales, up from 20% in 2023.
Lastly, the Ostomy Care division was highlighted for its robust growth, particularly in new patient starts in the United States and the strong adoption of Esteem Body in both Europe and the U.S. In emerging markets, double-digit growth was reported in key regions such as Brazil, Colombia, and China. Notably, this growth in China was achieved without the launch of Esteem Body in that market.
The positive outlook from ConvaTec's management, along with the raised guidance, has led to a relief rally in the company's shares, which saw an increase of around 20%, in contrast to the broader market's slight decline. Barclays continues to view ConvaTec favorably, citing a more balanced growth profile across its business segments.
In other recent news, medical products and technologies company, ConvaTec Group Plc, has undergone a revision of its share target by Morgan Stanley (NYSE:MS).
The firm has lowered the target from GBP2.97 to GBP2.83, while maintaining an Overweight rating on the stock. This adjustment comes in the wake of ConvaTec's first half of 2024 results, which have shaped analysts' expectations. Despite near-term concerns due to low-cost competition, Morgan Stanley remains positive about ConvaTec's de-risked earnings and risk-reward profile.
In addition to Morgan Stanley's revised price target, Berenberg has maintained its Buy rating on ConvaTec. This decision was made despite the company's first-half results, which were marked by ongoing uncertainty and weaker-than-expected margins. Berenberg's outlook remains unchanged, emphasizing the importance of ConvaTec's reaffirmed revenue and margin guidance for the year 2024.
These are recent developments that reflect the company's confidence in achieving its financial targets, despite initial setbacks.
InvestingPro Insights
To complement Barclays' positive outlook on ConvaTec Group Plc (OTC: CNVVY), recent data from InvestingPro provides additional context to the company's financial position and market performance.
ConvaTec's market capitalization stands at $6.84 billion, reflecting its significant presence in the medical devices industry. The company's P/E ratio of 34.3 (adjusted for the last twelve months as of Q2 2024) suggests that investors are willing to pay a premium for its shares, likely due to the growth prospects highlighted in the management presentation.
InvestingPro Tips indicate that ConvaTec is trading at a low P/E ratio relative to its near-term earnings growth, with a PEG ratio of 0.32. This aligns with the company's projection of double-digit EPS growth in 2025 and supports Barclays' Overweight rating.
The company's revenue growth of 5.61% over the last twelve months and a gross profit margin of 55.89% demonstrate its ability to expand sales while maintaining healthy profitability. This is particularly relevant given management's confidence in margin improvement for the latter half of 2024 and into 2025.
For investors seeking more comprehensive analysis, InvestingPro offers 7 additional tips for ConvaTec, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.